Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 48570 | 1.98 |
09:34 ET | 101542 | 1.99 |
09:36 ET | 22402 | 1.9592 |
09:38 ET | 75509 | 1.9907 |
09:39 ET | 13741 | 2 |
09:41 ET | 92287 | 1.9821 |
09:43 ET | 16404 | 1.9813 |
09:45 ET | 13640 | 1.98 |
09:48 ET | 114865 | 1.9907 |
09:50 ET | 89134 | 1.99 |
09:52 ET | 105899 | 2 |
09:54 ET | 101666 | 1.99 |
09:56 ET | 2149 | 1.9912 |
09:57 ET | 20590 | 1.995 |
09:59 ET | 6013 | 1.995 |
10:01 ET | 3826 | 1.995 |
10:03 ET | 12684 | 1.995 |
10:06 ET | 2552 | 1.9993 |
10:08 ET | 72304 | 1.975 |
10:10 ET | 14140 | 1.985 |
10:12 ET | 12650 | 1.985 |
10:14 ET | 2934 | 1.98 |
10:15 ET | 81699 | 1.995 |
10:17 ET | 74165 | 2 |
10:19 ET | 13158 | 2.001 |
10:21 ET | 5556 | 2 |
10:24 ET | 22329 | 2 |
10:26 ET | 29504 | 2 |
10:28 ET | 68006 | 1.985 |
10:30 ET | 14208 | 1.99 |
10:32 ET | 2007 | 1.9801 |
10:33 ET | 1716 | 1.99 |
10:35 ET | 55562 | 1.995 |
10:37 ET | 76291 | 2 |
10:39 ET | 41843 | 2 |
10:42 ET | 34896 | 2 |
10:44 ET | 83471 | 1.985 |
10:46 ET | 6600 | 1.985 |
10:48 ET | 100 | 1.985 |
10:50 ET | 4000 | 1.99 |
10:51 ET | 820 | 1.99 |
10:53 ET | 1384 | 1.99 |
10:55 ET | 1000 | 1.985 |
10:57 ET | 2720 | 1.99 |
11:00 ET | 2513 | 1.99 |
11:02 ET | 42708 | 2 |
11:04 ET | 12418 | 1.995 |
11:06 ET | 5050 | 1.9976 |
11:08 ET | 6180 | 1.995 |
11:09 ET | 6300 | 1.995 |
11:11 ET | 1600 | 2 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 151.2M | 10.1x | --- |
Spero Therapeutics Inc | 86.2M | 4.0x | --- |
2Seventy Bio Inc | 243.1M | -1.1x | --- |
Rigel Pharmaceuticals Inc | 166.2M | -8.5x | --- |
Alimera Sciences Inc | 171.8M | -1.6x | --- |
Seres Therapeutics Inc | 135.3M | -1.7x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $151.2M |
---|---|
Revenue (TTM) | $119.2M |
Shares Outstanding | 77.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.17 |
EPS | $0.20 |
Book Value | $-0.70 |
P/E Ratio | 10.1x |
Price/Sales (TTM) | 1.3 |
Price/Cash Flow (TTM) | 8.1x |
Operating Margin | 9.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.